Hillstar Bio
Latest round
- Series A
Last raised
- Sep 2023
Total raised
- $28M
Investors
- 5
About Hillstar Bio
Hillstar Bio is a biopharmaceutical company focused on developing innovative treatments to address unmet medical needs in various therapeutic areas using advanced biotechnological processes., Frazier Healthcare Partners, Droia Ventures.. Hillstar Bio specializes in the development of innovative biopharmaceutical products aimed at addressing significant unmet medical needs. The company's core offerings focus on therapeutic solutions designed to improve patient outcomes in various therapeutic areas. These products involve advanced biotechnological processes, harnessing the power of biologics to create treatments that enhance the efficacy and safety of existing therapies. Hillstar Bio serves a diverse clientele, including healthcare providers, hospitals, and research institutions, primarily within the North American and European markets. The revenue structure of Hillstar Bio is primarily derived from partnerships and collaborations with healthcare institutions and pharmaceutical companies. Transactions typically occur through a B2B model, where the company offers subscription-based access to its proprietary therapies, along with research and development services. Hillstar Bio's flagship products are offered through a direct sales approach, ensuring that healthcare providers have immediate access to their innovative solutions. The pricing structure reflects the value of the advanced biopharmaceutical technologies provided, supporting both the initial sale and ongoing access for clients, establishing recurring revenue streams and ensuring a steady market presence., Frazier Healthcare Partners, Droia Ventures, which will be utilized to advance its lead TRBV9 program through clinical trials for axial spondyloarthritis and to expand its pipeline of precision immunology therapies targeting autoimmune diseases. The company is also planning to explore new geographic markets in Europe and North America by late 2026, aiming to broaden the reach of its innovative therapeutic solutions.
Who invested in Hillstar Bio
5 investors across 1 round
See all investors in Hillstar Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 18, 2023
Amount
$28M
Investors
Questions about Hillstar Bio
Who invested in Hillstar Bio?
Hillstar Bio has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hillstar Bio raised?
Hillstar Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hillstar Bio last raise money?
Hillstar Bio's most recent round on record is a Series A, in Sep 2023.
What does Hillstar Bio do?
Hillstar Bio is a biopharmaceutical company focused on developing innovative treatments to address unmet medical needs in various therapeutic areas using advanced biotechnological processes.
Where is Hillstar Bio headquartered?
Hillstar Bio is headquartered in Boston, US.
Which VCs invest in companies like Hillstar Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Hillstar Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Hillstar Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.